سعر فيرماجون 120مجم 2 فيال 2024

Degarelix 120 mg powder for solution for subcutaneous injection, pack of 2 vials (Ferring Pharmaceuticals; Egyptian agent listed as Multipharma). After reconstitution the solution contains 40 mg/ml degarelix (EU SmPC).

• Treatment of adult male patients with advanced hormone-dependent prostate cancer.Population: Adult menEuropean Medicines Agency (EMA)
• Treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.Population: Adult menEuropean Medicines Agency (EMA)
• Neo-adjuvant treatment prior to radiotherapy in high-risk localised or locally advanced hormone-dependent prostate cancer.Population: Adult menEuropean Medicines Agency (EMA)

• Very common: hot flush and injection site reactions (mainly pain and erythema, mostly with the starting dose).International label, same formulation · European Medicines Agency (EMA)
• Common: anaemia, weight increase, insomnia, dizziness, headache, diarrhoea, nausea, increased liver transaminases, hyperhidrosis (including night sweats), rash, musculoskeletal pain, gynaecomastia, testicular atrophy, erectile dysfunction, chills, pyrexia, fatigue and influenza-like illness.International label, same formulation · European Medicines Agency (EMA)
• Uncommon: QT prolongation, cardiac arrhythmia, hypersensitivity, osteoporosis/osteopenia, hyperglycaemia/diabetes; rare: myocardial infarction, cardiac failure, anaphylactic reactions, neutropenic fever and rhabdomyolysis.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to degarelix or to any of the excipients.International label, same formulation · European Medicines Agency (EMA)
• History of severe hypersensitivity to degarelix or any product component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Long-term androgen deprivation therapy may prolong the QT interval; benefit/risk must be appraised in patients with QTc over 450 msec, risk factors for torsades de pointes or on QT-prolonging medicines.International label, same formulation · European Medicines Agency (EMA)
• Long periods of testosterone suppression can be expected to reduce bone density.International label, same formulation · European Medicines Agency (EMA)
• Reduced glucose tolerance may occur with androgen deprivation; diabetic patients may need more frequent blood glucose monitoring.International label, same formulation · European Medicines Agency (EMA)

• QT-prolonging medicines (e.g. class IA/III antiarrhythmics such as quinidine, disopyramide, amiodarone, sotalol; methadone, moxifloxacin, antipsychotics)Androgen deprivation may prolong QTc, so concomitant use with medicines that prolong QTc or can induce torsades de pointes should be carefully evaluated.European Medicines Agency (EMA)

• There is no relevant indication for FIRMAGON in women. FIRMAGON may inhibit male fertility as long as testosterone is suppressed.International label, same formulation · European Medicines Agency (EMA)
• Safety and efficacy have not been established in women. Based on animal findings and mechanism of action, FIRMAGON can cause fetal harm and loss of pregnancy when given to a pregnant woman; no human data are available.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on degarelix in human milk, effects on the breastfed child or milk production; safety and efficacy are not established in females.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Degarelix: Selective GnRH antagonist that competitively and reversibly binds pituitary GnRH receptors, rapidly reducing LH and FSH release and thus testicular testosterone secretion, without an initial LH/testosterone surge (EU SmPC 5.1).